Head-to-head
Semaglutide vs Retatrutide
A field-by-field comparison of Semaglutide and Retatrutide drawn from the PeptideIndex database: mechanism, evidence grade, half-life, administration route, reported dosing, side effects, storage and legal status. Both are indexed as metabolic compounds, so the useful question is how they differ within that category.
Semaglutide vs Retatrutide: editorial summary
Semaglutide and retatrutide are both long-acting metabolic peptides, but they represent different stages of development and different receptor strategies. Semaglutide is an established GLP-1 receptor agonist with extensive clinical evidence and approved indications. Retatrutide is an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors.
Key considerations
- The fundamental difference is receptor activity. Semaglutide acts through the GLP-1 receptor, whereas retatrutide combines GLP-1 and GIP activity with glucagon-receptor activation. That additional glucagon pathway is intended to influence energy expenditure and hepatic lipid metabolism alongside appetite and glucose regulation.
- Evidence maturity is another major distinction. Semaglutide has a large clinical evidence base and regulatory approvals. Retatrutide remains investigational, so promising trial results do not carry the same regulatory or long-term safety status as an approved medicine.
Semaglutide characteristics
- Semaglutide is a GLP-1 analogue with Strong evidence on PeptideIndex. Its approximately one-week half-life supports once-weekly administration, and it has approved prescription indications.
Retatrutide characteristics
- Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist. PeptideIndex rates its evidence Strong based on clinical trial evidence but records it as investigational rather than FDA-approved.
Semaglutide vs Retatrutide at a glance
| Attribute | Semaglutide | Retatrutide |
|---|---|---|
| Category | Metabolic | Metabolic |
| Evidence grade | Strong | Strong |
| Also known as | Ozempic, Wegovy | LY3437943, Triple G |
| Chain | GLP-1 analogue, 94% homology to human GLP-1 | 39 amino acid triple GIP / GLP-1 / glucagon receptor agonist |
| Mechanism | Mimics GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying and act on hypothalamic appetite centres. Fatty-acid acylation extends its half-life to once-weekly dosing. | Simultaneously activates GLP-1, GIP and glucagon receptors in a single peptide. The glucagon component increases energy expenditure and hepatic lipid oxidation, while GLP-1 and GIP suppress appetite, slow gastric emptying and improve glucose-dependent insulin secretion. |
| Reported benefits | ~15% mean body-weight reduction over 68 weeks in STEP-1 · Improved HbA1c and cardiovascular outcomes · Marked reduction in appetite and food noise | Up to ~24% mean weight loss at 12 mg over 48 weeks in phase 2 · Large reductions in HbA1c and liver fat · Improvements in blood pressure, triglycerides and LDL cholesterol |
| Reported side effects | Nausea and vomiting · Constipation or diarrhoea · Gallbladder issues · Contraindicated with medullary thyroid carcinoma history | Nausea and vomiting · Diarrhoea · Gallbladder issues · Mild resting heart-rate increase · Injection-site reaction |
| Half-life | About 7 days | About 5–7 days |
| Administration | Once-weekly subcutaneous injection (oral tablet also approved) | Once-weekly subcutaneous injection |
| Dosing overview | Label titration from 0.25 mg weekly up to 2.4 mg over 16+ weeks | Phase 2 started at 2 mg weekly and escalated to 12 mg over several weeks |
| Storage | Refrigerate 2–8 °C; in-use pens may be kept at room temperature per label | Investigational product; typically refrigerated as lyophilised or pen formulation |
| Legal status | FDA-approved and prescription-only. | Investigational drug; not FDA-approved as of 2026. |
Key differences between Semaglutide and Retatrutide
Both are metabolic compounds
Semaglutide and Retatrutide are both indexed under metabolic, so they compete for the same use case rather than complementing each other. Semaglutide: "A long-acting GLP-1 receptor agonist with the strongest clinical weight-loss evidence of any peptide on the market." Retatrutide: "A once-weekly 'triple G' agonist that produced the largest weight reductions of any incretin-class molecule in phase 2 obesity trials."
Mechanism of action
Semaglutide: Mimics GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying and act on hypothalamic appetite centres. Fatty-acid acylation extends its half-life to once-weekly dosing. Retatrutide: Simultaneously activates GLP-1, GIP and glucagon receptors in a single peptide. The glucagon component increases energy expenditure and hepatic lipid oxidation, while GLP-1 and GIP suppress appetite, slow gastric emptying and improve glucose-dependent insulin secretion.
Half-life and dosing frequency
Semaglutide is listed at about 7 days; Retatrutide at about 5–7 days. That difference is what drives the reported schedules: Label titration from 0.25 mg weekly up to 2.4 mg over 16+ weeks versus Phase 2 started at 2 mg weekly and escalated to 12 mg over several weeks
Route of administration
Semaglutide is administered by once-weekly subcutaneous injection (oral tablet also approved). Retatrutide is administered by once-weekly subcutaneous injection.
Legal and regulatory status differs
Semaglutide: FDA-approved and prescription-only. Retatrutide: Investigational drug; not FDA-approved as of 2026. This is usually the most practical difference between two compounds, because it determines whether a supply chain is labelled and regulated at all.
Handling and storage
Semaglutide is stored refrigerate 2–8 °c; in-use pens may be kept at room temperature per label. Retatrutide is stored investigational product; typically refrigerated as lyophilised or pen formulation.
What Semaglutide and Retatrutide have in common
- Category: both listed as Metabolic
- Evidence grade: both listed as Strong
Both profiles list the same reported side effects: nausea and vomiting, gallbladder issues.
Each compound in brief
Semaglutide
Metabolic · Strong evidence
A long-acting GLP-1 receptor agonist with the strongest clinical weight-loss evidence of any peptide on the market.
Considerations: Muscle loss can account for a meaningful share of weight lost — resistance training and protein intake matter · GI side effects are dose-dependent; titrate slowly · Weight regain is common after stopping
Retatrutide
Metabolic · Strong evidence
A once-weekly 'triple G' agonist that produced the largest weight reductions of any incretin-class molecule in phase 2 obesity trials.
Considerations: Still investigational; long-term cardiovascular and safety data are pending · Muscle-loss and GI tolerability concerns mirror semaglutide and tirzepatide · Dose must be escalated slowly to improve tolerability
Frequently asked questions
What is the main difference between semaglutide and retatrutide?
Semaglutide primarily activates the GLP-1 receptor, while retatrutide activates GLP-1, GIP and glucagon receptors.
Which has the more established evidence base?
Semaglutide has the more mature evidence and regulatory history. Retatrutide has promising clinical-trial evidence but remains investigational.
Are semaglutide and retatrutide approved medicines?
Semaglutide has approved prescription indications. Retatrutide is still an investigational drug according to the PeptideIndex database.
Related comparisons and reading
Every figure on this page is reproduced from the compound profiles in this database and reflects published literature and commonly reported protocols. It is educational information, not medical advice, and not a recommendation to use either compound. See the medical disclaimer.